Non-fucosylated Anti-Human Sclerostin Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ12] (CAT#: BioBet-012ZP) Datasheet

Target
Sclerostin
Isotype
Whole Humanized Antibody
Description
ADCC-enhanced Romosozumab is a non-fucosylated anti-Sclerostin therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-Sclerostin Romosozumab, a biobetter by reducing fucosylation of the Fc region of Romosozumab, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Severe Eosinophilic Asthma
Classification
Therapeutic antibody; biobetter
Patent
Not Available
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Romosozumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SOST
Full Name
sclerostin
Background
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.
Alternative Names
SOST; sclerostin; CDD; VBCH; SOST1
Gene ID
UniProt ID
Cellular Localization
Extracellular region or secreted
HGNC
OMIM
Involvement in Disease
Diseases associated with SOST include Sclerosteosis 1 and Craniodiaphyseal Dysplasia, Autosomal Dominant.
Related Pathways
Its related pathways are Signaling by GPCR and Signaling by Wnt.
Function
Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.
Post-translational modifications
Glycosylation at Asn53 and Asn175
Trade name
Evenity
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB11866
CAS number
909395-70-6
Antibody Isotype
Whole Humanized Antibody
Antibody Clone
Romosozumab
Description
Romosozumab is a humanized monoclonal antibody that targets sclerostin. It is used in postmenopausal women with a high risk of fracture and in patients who have failed treatment or are intolerant to other osteoporosis treatments. Osteoporosis in the treatment of osteoporosis. Studies have shown that the drug can increase bone formation and reduce bone resorption in postmenopausal women with low bone density. Romolimumab is approved for medical use in the United States in 2019. Romosozumab is sold in the United States by Amgen under the trade name Evinity.
Indication
Osteoporosis
Synonyms
Not Available
UNII
3VHF2ZD92J

Osteoblasts secrete sclerostin, which promotes bone resorption through two mechanisms: a. Inhibition of bone formation by binding to low-density lipoprotein (LDL) receptor-related proteins 5 and 6 of osteoblasts, thereby inhibiting the Wnt signaling pathway; b Increase the production of nuclear factor kappa-ligand (RANKL) 2 receptor activators to promote bone resorption.
Romosozumab targets and inhibits sclerostin, and on the one hand prevents the inhibition of bone formation by allowing Wnt to bind to LDL receptor-related proteins. Activation of the Wnt pathway leads to promotion of osteoblast survival and proliferation; on the other hand, the inhibitory effect of Romosozumab on sclerostin also inhibits RANKL-dependent osteoclast activity and bone resorption.
Autoimmune diseases
Osteoporosis

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK